a public good project by the
Synthesis
Company
of California

© 2026

T Haas | doi.page

0 works0 citations0 h-index

T Haas

Novartis (Switzerland)(CH)

Publications by Year

Research Areas

Cardiovascular Health and Disease Prevention, Acute Myeloid Leukemia Research, Diabetes, Cardiovascular Risks, and Lipoproteins, Regulation of Appetite and Obesity, Cerebrovascular and Carotid Artery Diseases

Most-Cited Works

→ Everolimus for Advanced Pancreatic Neuroendocrine Tumors(2011)2,831 cited
→ Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis(2006)1,051 cited
→ Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
→ Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial(2009)649 cited
→ Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection(2016)321 cited
→ Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized Studies(2004)257 cited

→ Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma(2018)

251 cited

→ Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study(2004)191 cited

→ Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma(2022)146 cited

→ Comparison of the Insulin Action Parameters from Hyperinsulinemic Clamps with Homeostasis Model Assessment and QUICKI Indexes in Subjects with Different Endocrine Disorders(2004)105 cited